Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VericelVCEL -0.86%84 10-Year Share Buyback Ratio is -6.20 as of Jun. 2026. GuruFocus rates VCEL with a GF Score™ of 84/100 and a GF Value™ of $53.25 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 669 Biotechnology companies, Vericel ranks better than 66.07% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Vericel's current 10-Year Share Buyback Ratio was -6.20%.
VCEL's 10-Year Share Buyback Ratio is ranked better than 66.07% of 669
companies
in the Biotechnology industry
Industry Median: -11.7
vs VCEL: -6.20
Vericel (NAS:VCEL) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Vericel 10-Year Share Buyback Ratio Related Terms
VCEL vs KLRA, MLYS, NUVB: 10-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Vericel's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel 10-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Vericel's 10-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -6.20 mean?
Vericel (VCEL) has a 10-Year Share Buyback Ratio of -6.20 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Vericel and its competitors. According to the industry distribution chart, Vericel ranks #227 out of 669 companies in the Biotechnology industry, placing it in the top 33.9%.
Is Vericel's 10-Year Share Buyback Ratio too high?
Vericel's current 10-Year Share Buyback Ratio is -6.20. Based on the distribution chart, Vericel ranks #227 out of 669 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vericel has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's 10-Year Share Buyback Ratio compare to KLRA and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #227 out of 669 companies for 10-Year Share Buyback Ratio. This puts Vericel in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Vericel and its competitors. Vericel's current 10-Year Share Buyback Ratio is -6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $53.25, compared to a current price of $45.93 — trading 13.7% below its estimated fair value. The current 10-Year Share Buyback Ratio is -6.20. Vericel's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Vericel (VCEL), the current 10-Year Share Buyback Ratio is -6.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $45.93 is trading 13.7% below its estimated GF Value™ of $53.25.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
10-Year Share Buyback Ratio: -6.20
GF Value™: $53.25 vs. price of $45.93 (13.7% below fair value)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
84GF Score
Get the complete analysis for VCEL
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
